Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1995 Nov 1;311(Pt 3):867–872. doi: 10.1042/bj3110867

An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine).

R Wang 1, M E Klegerman 1, I Marsden 1, M Sinnott 1, M J Groves 1
PMCID: PMC1136081  PMID: 7487943

Abstract

Tice substrain BCG is used clinically as an immunotherapeutic agent against superficial bladder cancer. A boiling-water extract of this BCG showed anti-tumour activity against a murine S180 sarcoma model and was fractionated into three fractions, A, B and C, by the use of Sephadex LH-20 chromatography. An anti-tumour glucan, PS1A1, was isolated from fraction PS1A with Sephadex G-75. The molecular mass of PS1A1 was between 65 and 87 kDa by Sephadex G-100 chromatography. The structure of PS1A1 was investigated by one- and two-dimensional NMR spectroscopy and methylation analysis and was demonstrated to be primarily 1-->6-alpha-linked glucose units. We postulate that the repeating unit is: [Formula: see text]

Full text

PDF
868

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Davies M. Bacillus Calmette-Guérin as an anti-tumor agent. The interaction with cells of the mammalian immune system. Biochim Biophys Acta. 1982 Apr 29;651(2-3):143–174. doi: 10.1016/0304-419x(82)90010-5. [DOI] [PubMed] [Google Scholar]
  2. Gross N. J., Eddie-Quartey A. C. Immune status in lung cancer: effects of BCG immunotherapy. Am Rev Respir Dis. 1976 Apr;113(4):457–464. doi: 10.1164/arrd.1976.113.4.457. [DOI] [PubMed] [Google Scholar]
  3. Groves M. J. Pharmaceutical characterization of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine used for the treatment of superficial bladder cancer. J Pharm Sci. 1993 Jun;82(6):555–562. doi: 10.1002/jps.2600820602. [DOI] [PubMed] [Google Scholar]
  4. Harris P. J., Henry R. J., Blakeney A. B., Stone B. A. An improved procedure for the methylation analysis of oligosaccharides and polysaccharides. Carbohydr Res. 1984 Apr 2;127(1):59–73. doi: 10.1016/0008-6215(84)85106-x. [DOI] [PubMed] [Google Scholar]
  5. Klegerman M. E., Ujjainwala L., Zeunert P. High-dose inhibition and low-dose enhancement of murine sarcoma growth exhibited by BCG vaccine. Cancer Lett. 1991 Feb;56(2):137–145. doi: 10.1016/0304-3835(91)90088-y. [DOI] [PubMed] [Google Scholar]
  6. Klegerman M. E., Zeunert P. L., Lajeune J., Lou Y., Groves M. J. Relative tumor inhibitory and stimulatory activities of BCG vaccine preparations, lots and substrains in a quantitative mouse sarcoma bioassay. Anticancer Res. 1991 Sep-Oct;11(5):1707–1710. [PubMed] [Google Scholar]
  7. Lamm D. L. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 1985 Jul;134(1):40–47. doi: 10.1016/s0022-5347(17)46972-2. [DOI] [PubMed] [Google Scholar]
  8. Lou Y., Klegerman M. E., Muhammad A., Dai X., Groves M. J. Initial characterization of an antineoplastic, polysaccharide-rich extract of Mycobacterium bovis BCG, Tice substrain. Anticancer Res. 1994 Jul-Aug;14(4A):1469–1475. [PubMed] [Google Scholar]
  9. Mitchell M. S., Murahata R. I. Modulation of immunity by bacillus Calmette-Guérin (BCG). Pharmacol Ther. 1979;4(2):329–353. doi: 10.1016/0163-7258(79)90141-4. [DOI] [PubMed] [Google Scholar]
  10. Nightingale S. L. From the Food and Drug Administration. JAMA. 1990 Aug 8;264(6):677–677. [PubMed] [Google Scholar]
  11. Zang L. H., Howseman A. M., Shulman R. G. Assignment of the 1H chemical shifts of glycogen. Carbohydr Res. 1991 Nov 11;220:1–9. doi: 10.1016/0008-6215(91)80001-4. [DOI] [PubMed] [Google Scholar]
  12. Zbar B., Bernstein I. D., Rapp H. J. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971 Apr;46(4):831–839. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES